
# Neuromuscular Complications of Critical Illness

Jeffrey A Strakowski, M.D. Kauai 2013

> Medical Center



## Critical Illness Neuromuscular Disorders

- Common
- Poorly understood
- Serious functional consequences




# Neuromuscular Complications of Critical Illness

#### History

- Muscular wasting as a consequence of sepsis - Sir William Osler - 1892
- Unexplained neuropathic complications in critically ill patients Olsen 1956
- Coma-polyneuropathies described by Mertens - 1961
- Polyneuropathy in burn patients
   Henderson 1971
- Polyneuropathy in septic patients - Bischoff - 1977
- Development of the term Critical Illness Polyneuropathy – 1984 (Bolton)

- Polyneuropathy in a patient with an anoxic brain injury -Erbsloh and Abel - 1989
- Polyneuropathy associated with the use of nondepolarizing NMBA
- Myopathy in patients with asthma who were treated with NMBA and corticosteroids
- CIP is the most common acute polyneuropathy in the critically ill patient -2003








NERVE AND SITE OF STIMULATION	LATENCY	AMPLITUDE	DURATION	VELOCITY	<ul> <li>34<sup>th</sup> day post onset</li> </ul>
	msec	μV	msec	m/sec	No conduction block
M			001120204012		<ul> <li>Needle EMG</li> </ul>
Motor nerve					No fibs or PSW
Median					
Wrist	3.5	1480	9.4	50	<ul> <li>MUPs ↑ polys</li> </ul>
Elbow	7.9	1430	10.3	52	<ul> <li>NI to low amp</li> </ul>
Ulnar Wrist	2.0	1190	10.0		<ul> <li>Shorter duration</li> </ul>
wrist Below elbow	2.0 5.2	1060	10.0	56	
Above elbow	5.2 7.4	1130	10.5	50 68	<ul> <li>Recruitment WNL</li> </ul>
Tibial	7.4	1150	10.0	00	<ul> <li>F-wave lat WNL</li> </ul>
Ankle	4.4	3120	6.8		
Knee	13.0	2960	7.1	44	<ul> <li>Low amp</li> </ul>
Sensory nerve	2010				<ul> <li>Rep stim WNL</li> </ul>
Median	2.3	12.4		57	
Ulnar	2.0	7.0		50	
Sural	2.8	7.3		46	

# **Muscle Biopsy**

- Right deltoid
- Atrophy of both Type 1&2 fibers
- No inflammation
- No fiber-type
- grouping







# Patterns of neurophysiological abnormality in 44 long stay critically ill patients

Group	n (	%)	CMAP	SAP	Muscle biopsy	
Ĭ	7	(16)	Normal	Normal	Normal (2)	
	4	(9)	Normal	Reduced	Diffuse fibre atrophy (1) Diffuse fibre atrophy (2) Type II fibre atrophy (1)	
Ш	11	(25)	Reduced	Normal	Diffuse fibre atrophy (3)	
IV	19	(43)	Reduced	Reduced	Neurogenic atrophy (2) Myopathy (3) Diffuse fibre atrophy (6) Neurogenic atrophy (1) Myopathy (3)	
٧	3	(7)	Not classified	Not classified	Myopathy (2)	
potentia	al; S	SAP, s	sensory action p	ootential.	mpound muscle action	
Coa	K	ey e	et al, 1998			

	NO CIP	CIP	р
Number	20	18	
Mean age (years)	54.7±17.3	58.5 ±17.0	0.49
Mean number of ventilation days	20.3 ±10.9	33.6 ±19.8	0.02
Mean APACHE II in first 24 h	23.1 ±6.8	21.9 ±9.1	0.66
Mean maximal Muti Organ Dysfunction Syndrome (MODS) score	3.6 ±1.5	5.3 ±1.8	0.003
Median number (range) of days to reach maximum MODS score	1 (1-2)	4.5 (2-9)	0.002
Median number (range) of different organs involved (max 6)	2 (1-4)	4 (3-5)	0.009
Sepsis syndrome	8 (40%)	10 (56%)	0.34
Number of deaths in the ICU	4 (20%)	8 (44%)	0.11

Persistent neuromuscular and neurophysiologic abnormalities in long-term survivors of prolonged critical illness\*

Simon N. Fletcher, FRCA; Daniel D. Kennedy, FRCA; Indrajit R. Ghosh, MRCP; Vijay P. Misra, MRCP; Kevin Kiff, FRCA; John H. Coakley, MRCP; Charles J. Hinds, FRCP, FRCA

- In 21 of 22 patients remarkably consistent neurophysiological findings indicative of denervation and subsequent reinnervation up to 5 years after discharge.
- 1 patient who had developed a necrotizing myopathy had no persisting weakness and no evidence of denervation.



# Neuromuscular Complications Diagnostic Approach

 Think broadly!
 Long <u>differential</u> diagnosis, depending on the clinical context



#### History

- Medication (intravenous administration of corticosteroids panucuronium, vecuronium, metronidazole, amiodarone,
- Undiagnosed neuromuscular disorder (PM, DM, ALS, GBS, MG, LEMS, acid maltase deficiency, mitochondrial myopathy, musc. dystrophy)
- S pinal cord damage (ischemic, compressive hematoma, trauma)
- C ritical illness neuromuscular disorder
- Loss of muscle mass (disuse atrophy, rhabdomyolysis, catabolic state)
- E lectrolyte disorders (hypokalemia, hypermagnesemia, hypophosphatemia)
- Systemic illness (acute prophyria, AIDS, vasculitis neuropathy, endocrine myopathies)

(Wijdicks E.F.M., et.al, 1995)



Medical Center


# **Diagnostic Approach**


#### Examine the patient! Confirm weakness!


- Unexpected lack of ventilatory weaning
- Accelerated peripheral muscle atrophy

Medical Center

Inability to hold head/limb off bed







# Neuromuscular Complications of Critical Illness

#### <u>SIRS</u>

- Systemic Inflammatory Response Syndrome (SIRS) - The Society of Critical Care Medicine and The American College of Chest Physicians consensus conference 1992
- The severe systemic response that occurs in critically ill patients

- Etiology varied: infection (sepsis), trauma, burns etc.
- Septic Shock is a term reserved for individuals with organ dysfunction and hypoperfusion





# Neuromuscular Complications of Critical Illness

#### Physiology of SIRS

- Activation of humoral responses primarily involving the cytokines (interleukins, tumor necrosis factor, arachidonic acid, free oxygen radicals and proteases)
- Activation of cellular responses primarily involving lymphocytes, monocytes and neutrophils







### Myopathy in Critically III Individuals

Acute corticosteroid myopathy Acute quadriplegic myopathy (AQM) Acute myopathy in Status Asthmaticus (Acute) (necrotizing) myopathy of intensive care Critical care myopathy

- ICU myopathy
- Myopathy with thick filament (myosin) loss

# Neuromuscular Complications of Critical Illness\*

#### Neuropathy

- Critical Illness Polyneuropathy
- Acute Motor Neuropathy Associated with Non-Depolarizing Neuromuscular Blocking Agents

#### Critical Illness Myopathy


- Thick Filament Myopathy
- Acute Necrotizing Myopathy of Intensive Care
- Catabolic Myopathy

Neuromuscular Junction Abnormalities

Neuromyopathy

\*Studies in the pediatric population find a similar pattern of distributio

OHIO Medical Center



# **Neuromuscular Complications of Critical Illness**


## I. Neuropathy


#### **Critical Illness Polyneuropathy**

- Acute, diffuse, mainly motor neuropathy due to axonal dysfunction
- Patients with sepsis or multiple organ dysfunction
- Incidence in this patient population ranges from 50-75%
- Severity proportional to length of time in the ICU


Medical


삕 Center






# <section-header><section-header><section-header><section-header><list-item><list-item><list-item>







#### Neuromuscular Complications of Critical Illness


#### I. Neuropathy


#### **Critical Illness Polyneuropathy**


- Severe: absent SNAP, fibrillation potentials in all muscle groups, and multiple CMAP amplitudes less than 1mv amplitude
- Moderate: SNAP amplitudes <5uv, multiple CMAP amplitudes between 1 and 3 mV, fibrillation potentials and positive sharp waves in distal
   muscles and occasionally present in more proximal muscles
- Mild: SNAP amplitudes >5uv, CMAP amplitudes >3mv, occasional positive sharp waves in distal muscles

Spitzer AR, Giancarlo T, Maher L, et al. 1992











# <section-header><section-header><section-header><section-header><list-item>

#### Neuromuscular Complications of Critical Illness

#### I. Neuropathy

Acute Motor Neuropathy Associated with Non-Depolarizing Neuromuscular Blocking Agents

- Occurs more readily in patients with renal or hepatobiliary disease
- Neuropathy occurs as a result of a toxic effect of the non-depolarizing agent in a patient with SIRS
- Neuropathy is more likely the longer these agents are used




#### Neuromuscular Complications of Critical Illness


#### I. Neuropathy

Acute Motor Neuropathy Associated with Non-Depolarizing Neuromuscular Blocking Agents

- Significant increase in the incidence when these agents are used for >48 hours
- Presents as difficulty weaning from the ventilator and limb weakness











#### Neuromuscular Complications of Critical Illness II. Myopathy

#### **Thick Filament Myopathy**

- Occurs in patients with a sudden severe asthma exacerbation
- Patients who receive NMBA and high dose corticosteroids
- Incidence associated with the length of chemical paralysis







#### Neuromuscular Complications of Critical Illness II. Myopathy

# Thick Filament Myopathy

- Patients present with failure to wean and flaccid limb weakness of distal and proximal muscles
- Facial muscles are often affected
- Peripheral sensation is normal
- CPK levels are significantly increased
- Recovery is usually rapid



Medical Center

#### Neuromuscular Complications of Critical Illness II. Myopathy

### Electrodiagnostic Findings in Thick Filament Myopathy

- Motor nerve conduction velocities are usually normal
- Low amplitude CMAP
- Sensory studies are normal
- Repetitive nerve stimulation is normal
- Needle EMG reveals motor unit action potentials that are of short duration, low amplitude and polyphasic




#### Neuromuscular Complications of Critical Illness

### II. Myopathy

# Muscle Biopsy Finding in Thick Filament Myopathy

- Loss of structure centrally that is a result of destruction of the thick myosin filaments
- Pattern of atrophy, necrosis, and
  - regeneration of type I and II muscle fibers
- Little or no associated inflammation







# <section-header><section-header><section-header><list-item>


#### Neuromuscular Complications of Critical Illness

#### II. Myopathy

Acute Necrotizing Myopathy of Intensive Care

- Electrodiagnosis is consistent with a severe myopathy
- Muscle biopsy shows severe widespread muscle fiber necrosis
- Prognosis correlates with the severity of the myopathy





#### Neuromuscular Complications of Critical Illness II. Myopathy

#### **Catabolic Myopathy**

- Ill-defined
- Believed to result from the action of Interleukin-1 and tumor necrosis factor
- Defects in high-energy metabolites in patients with respiratory failure, cardiogenic shock, severe congestive heart failure, and sepsis





#### Neuromuscular Complications of Critical Illness

#### **Direct Muscle Stimulation**

- Direct Muscle Stimulation can help in distinguishing myopathy from peripheral neuropathy in the critically ill.
- In CIP the denervated muscles should retain electrical excitability and direct muscle stimulated CMAP should be normal. In Critical Illness Myopathy the muscle fibers lose excitability and thus the direct muscle and nerve stimulated CMAP are reduced








#### Neuromuscular Complications of Critical Illness III. Neuromuscular Junction Abnormalities


- Transient persistent neuromuscular blockade occurs with the use of non-depolarizing NMBA long after the medications are discontinued
- More likely to occur in patients with renal or liver disease


Medical Center

 Repetitive Nerve Stimulation reveals a neuromuscular transmission defect (decremental response)









# Critical Illness Polyneuropathy: A 2-Year Follow-Up Study in 19 <u>Severe</u> Cases

C	Case Day Sensory findings		Sensory findings	Follow up	
	1 12		Distal sensory loss	2 years:paraparesis	
	2	10	n.a.	Complete recovery within 3 m	
	3	30	Distal sensory loss	2 years:quadriplegia	
4	4	20	Distal sensory loss	Death at day 65 without recovery	
	5	20	Normal	Complete recovery within 3 m	
	6	13	Distal sensory loss	Complete recovery within 1y	
	7	7	n.a.	Complete recovery within 3m	
	8	30	Distal sensory loss	2 years after: quadriplegia	
	9	15	Distal sensory loss	Complete recovery within 6 months	
	10	29	Distal sensory loss	Death at day 168	

Seze et al, Eur Neurol 2000;43:61-69



Critical Illness Polyneuropathy: A 2-Year Follow-Up Study in 19 <u>Severe</u> Cases					
Case	Day	Sensory findings	Follow up		
11	33	Normal	Complete recovery within 3 m		
12	19	Normal	Complete recovery within 6 m		
13	23	Distal loss	Complete recovery within 1 y		
14	30	Distal sensory loss	Complete recovery within 6 m		
15	31	n.a.	Complete recovery within 6 m		
16	120	Normal	Complete recovery within 1 y		
17	10	Distal sensory loss	2 years: quadriparesis		
18	29	n.a.	Death at day 72 without recovery		
19	25	Distal sensory loss	Death at day 348		

Seze et al, Eur Neurol 2000;43:61-69



Persistent neuromuscular and neurophysiologic abnormalities in long-term survivors of prolonged critical illness\*

Simon N. Fletcher, FRCA; Daniel D. Kennedy, FRCA; Indrajit R. Ghosh, MRCP; Vijay P. Misra, MRCP; Kevin Kiff, FRCA; John H. Coakley, MRCP; Charles J. Hinds, FRCP, FRCA

- All 22 patients gave a clear history of prolonged weakness, fatigue and difficulty with mobility
- In some patients weakness was still clinically evident up to 4 yrs after discharge and in 1 was severe




Persistent neuromuscular and neurophysiologic abnormalities in long-term survivors of prolonged critical illness\*

Simon N. Fletcher, FRCA; Daniel D. Kennedy, FRCA; Indrajit R. Ghosh, MRCP; Vijay P. Misra, MRCP; Kevin Kiff, FRCA; John H. Coakley, MRCP; Charles J. Hinds, FRCP, FRCA

- Neurological examination
  - sensory deficits in 27%
  - motor weakness in 18%
  - sensory and motor deficits in 14%
  - bilateral peroneal nerve palsies in 2 patients
  - bilateral upper limb weakness in 3 patients









- Severe weakness, prolonged recovery and residual clinical motor and sensory neurological deficits are extremely common in survivors of protracted critical illness
- In those with mild or moderate CIP recovery is often relatively rapid and complete (weeks or months)







Much of Newer Literature Suggests Myopathy More Common

 Acute myopathy 3x as common as polyneuropathy --Lacomis M&N May 1998.

# Summary of Literature Review and Clinical Experience

- There is vast disparity in the medical literature.
- Much of the early literature appears unsatisfactory in adequately describing the conditions.
- The vast majority, at our institution, have a primarily myopathic influence.

# Deficiencies in the Early Literature Include:

- Initially studied primarily severely tetraparetic patients, resulting in little motor unit evaluation
- Only sporadic use of nerve and muscle biopsies
- No use of direct muscle stimulation
- Over-interpreted absent F-waves

Complicating Factors in ICU Assessment


- Poor mobility
- Frequent cognitive impairments and sedation
- Frequent limb edema
- Often co-morbid factors (eg diabetes mellitus, CRF)



- Described as a "motor predominant" axonopathy because it's a myopathy!
- Rarely sensory symptoms or signs in communicative patients
- Virtually never neuropathic pain
- Little to no membrane instability

# Myopathy not Axonopathy

- Many short duration, small amplitude polyphasic MUAPs
- "Early" Recruitment!
- Little to no improvement with direct muscle stimulation
- Involves proximal and distal muscles equally




# Many Cases Appear to be "Membranopathies"

• Normal histology and rapid recovery

 Presumption: The muscle membrane becomes dysfunctional, inexcitable and leaky

Resultant loss of myoglobin



Combination of Neuropathy and Myopathy is not Uncommon

# My Opinion

 Electrodiagnosis remains the most practical and comprehensive testing for ICU weakness

# **Electrodiagnostic Approach**

Need to assess for neuropathy, myopathy, primary NMJ disorder, motor neuron disease, central weakness


## **Electrodiagnostic Approach**

- Neuropathy: CIP, DM, Other pre-morbid, AIDP, CIDP, MMN
- Myopathy: CIM, PM, other inflammatory, congenital
- NMJ: MG, MS, Botulinum
- MND
- Central: CVA, Cervical myelopathy
- Co-morbid conditions

## **Electrodiagnostic Approach**

- Motor NCS with F-waves
- Include phrenic studies if indicated
- Sensory studies
- Repetitive Stimulation including fast stimulation or (preferably) post-exercise
- Needle EMG
- If needed, direct muscle stimulation

Note: Will generally sample at least three limbs of the above



# Summary

 Comprehensive clinical and electrodiagnostic evaluation can provide an effective evaluation of generalized weakness in the ICU.